S
Steven J. Reed
Researcher at Infectious Disease Research Institute
Publications - 6
Citations - 434
Steven J. Reed is an academic researcher from Infectious Disease Research Institute. The author has contributed to research in topics: Adjuvant & Immune system. The author has an hindex of 6, co-authored 6 publications receiving 381 citations.
Papers
More filters
Journal ArticleDOI
A synthetic adjuvant to enhance and expand immune responses to influenza vaccines.
Rhea N. Coler,Susan L. Baldwin,Narek Shaverdian,Sylvie Bertholet,Steven J. Reed,Vanitha S. Raman,Xiuhua Lu,Joshua DeVos,Kathy Hancock,Jacqueline M. Katz,Thomas S. Vedvick,Malcolm S. Duthie,Christopher H. Clegg,Neal Van Hoeven,Steven G. Reed +14 more
TL;DR: Results suggest that synthetic TLR4 adjuvants can enhance the magnitude and quality of protective immunity induced by influenza vaccines.
Journal ArticleDOI
From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.
Rhea N. Coler,Malcolm S. Duthie,Kimberly A. Hofmeyer,Jeffery Guderian,Lakshmi Jayashankar,Julie Vergara,Tom Rolf,Ayesha Misquith,John D. Laurance,Vanitha S. Raman,H. Remy Bailor,Natasha Dubois Cauwelaert,Steven J. Reed,Aarthy C. Vallur,Michelle Favila,Mark T. Orr,Jill A. Ashman,Prakash Ghosh,Dinesh Mondal,Steven G. Reed +19 more
TL;DR: The vaccine candidate was shown to be safe and induced a strong antigen‐specific immune response, as evidenced by cytokine and immunoglobulin subclass data, which provide a strong rationale for additional trials in Leishmania‐endemic countries in populations vulnerable to VL.
Journal ArticleDOI
Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL‐18, and IFN‐γ
Anthony L. Desbien,Steven J. Reed,Hilton R. Bailor,Natasha Dubois Cauwelaert,John D. Laurance,Mark T. Orr,Christopher B. Fox,Darrick Carter,Steven G. Reed,Malcolm S. Duthie +9 more
TL;DR: It is demonstrated that IL‐18 and caspase‐1/11 are components of the response to immunization with the TLR4 agonist/squalene oil‐in‐water based adjuvant, GLA‐SE, providing implications for other adjuvants that combine oils with TLR agonists.
Journal ArticleDOI
Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis.
Malcolm S. Duthie,Michelle Favila,Kimberly A. Hofmeyer,Yeung L. Tutterrow,Steven J. Reed,John D. Laurance,Alessandro Picone,Jeffrey A. Guderian,H. Remy Bailor,Aarthy C. Vallur,Hong Liang,Raodoh Mohamath,Julie Vergara,Randall F. Howard,Rhea N. Coler,Steven G. Reed +15 more
TL;DR: Data indicate a novel recombinant vaccine antigen with the potential for use in VL control programs, and a chimeric fusion protein comprising a combination of the 8E, p21 and SMT proteins was demonstrated to protect against L. donovani infection.
Journal ArticleDOI
IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants.
Anthony L. Desbien,Natasha Dubois Cauwelaert,Steven J. Reed,Hilton R. Bailor,Hong Liang,Darrick Carter,Darrick Carter,Malcolm S. Duthie,Malcolm S. Duthie,Christopher B. Fox,Christopher B. Fox,Steven G. Reed,Steven G. Reed,Mark T. Orr,Mark T. Orr +14 more
TL;DR: The synthetic TLR4 agonist glycopyranosyl lipid adjuvant formulated in a squalene-in-water emulsion (GLA-SE) augments both cellular and humoral immune responses to vaccine Ags.